Cargando…
A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir
Oral direct-acting antivirals comprise the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the primary agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. Ombitasvir/paritaprevir/ritonavir was also recommended as a therap...
Autores principales: | Tarao, Kazuo, Sato, Akira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803708/ https://www.ncbi.nlm.nih.gov/pubmed/29430226 http://dx.doi.org/10.1159/000484135 |
Ejemplares similares
-
Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment
por: Weiss, Lina, et al.
Publicado: (2018) -
A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir
por: Tarao, Kazuo, et al.
Publicado: (2017) -
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
por: Bell, Allison M., et al.
Publicado: (2016) -
Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
por: Morikawa, Kenichi, et al.
Publicado: (2018) -
Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients
por: Ji, Qinghua, et al.
Publicado: (2021)